Number of drugs approved by Health Canada and evaluated by the Patented Medicine Prices Review Board and/or Prescrire International, 1997–2012
| Health Canada | Patented Medicine Prices Review Board/Prescrire International | Agreement between Health Canada and Patented Medicine Prices Review Board/Prescrire International (κ) | ||||
|---|---|---|---|---|---|---|
| Year | Number of approved | N (%) with priority review | Number of evaluated | N (%) assessed as innovative | N (%) given priority review | |
| 1997 | 42 | 8 (19.0) | 24 | 4 (16.7) | 4 (16.7) | 0.400 |
| 1998 | 30 | 2 (6.7) | 24 | 2 (8.3) | 2 (8.3) | −0.091 |
| 1999 | 36 | 12 (33.3) | 31 | 4 (9.7) | 10 (32.3) | 0.006 |
| 2000 | 26 | 11 (42.3) | 20 | 4 (20.0) | 9 (45.0) | 0.468 |
| 2001 | 27 | 9 (33.3) | 23 | 4 (17.4) | 7 (30.4) | 0.495 |
| 2002 | 24 | 4 (16.7) | 20 | 1 (5.0) | 4 (20.0) | −0.087 |
| 2003 | 20 | 7 (35.0) | 19 | 2 (10.5) | 8 (42.1) | 0.336 |
| 2004 | 29 | 9 (31.0) | 27 | 4 (14.8) | 8 (29.6) | 0.585 |
| 2005 | 24 | 10 (41.7) | 21 | 4 (19.0) | 8 (38.1) | 0.106 |
| 2006 | 23 | 9 (39.1) | 21 | 6 (28.6) | 8 (38.1) | 0.152 |
| 2007 | 24 | 7 (29.2) | 22 | 4 (18.2) | 7 (31.8) | 0.488 |
| 2008 | 17 | 2 (11.8) | 15 | 2 (13.3) | 2 (13.3) | 0.423 |
| 2009 | 27 | 6 (22.2) | 26 | 3 (11.5) | 6 (23.1) | 0.081 |
| 2010 | 22 | 2 (9.1) | 18 | 2 (11.1) | 2 (11.1) | 1.000 |
| 2011 | 35 | 7 (20.0) | 20 | 3 (15.0) | 4 (20.0) | 0.828 |
| 2012 | 20 | 6 (30.0) | 14 | 3 (21.4) | 2 (14.3) | 0.276 |
| Total | 426 | 111 (26.1) | 345 | 52 (15.1) | 91 (26.4) | 0.330 |